[{"address1": "5750 Explorer Drive", "address2": "Suite 404", "city": "Mississauga", "state": "ON", "zip": "L4W 0A9", "country": "Canada", "phone": "905 602 5840", "website": "https://www.cipherpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of f severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Lipofen, which is indicated as adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, and to increase HDL-C, as well as to reduce triglycerides in adult patients; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include MOB-015, a topical formulation of terbinafine, which is in phase 3 clinical trial for treatment of onychomycosis; CF-101 (Piclidenoson) that is in phase 3 clinical trial for severe plaque psoriasis and rheumatoid arthritis; and DTR-001, a tattoo removal cream, which is in pre-clinical stage. The company was founded in 2000 and is headquartered in Mississauga, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig J. Mull", "title": "Interim CEO & Chairman of the Board", "fiscalYear": 2023, "totalPay": 82673, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Jacobs", "title": "President", "fiscalYear": 2023, "totalPay": 312851, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Mailling", "title": "Chief Financial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Emilio  Presti", "title": "Director of Sales & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hamed  Ghanei", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shengnan  Guo", "title": "Corporate Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 2, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 8.65, "open": 8.8, "dayLow": 8.78, "dayHigh": 8.95, "regularMarketPreviousClose": 8.65, "regularMarketOpen": 8.8, "regularMarketDayLow": 8.78, "regularMarketDayHigh": 8.95, "payoutRatio": 0.0, "beta": 0.948, "trailingPE": 19.45652, "forwardPE": 17.9, "volume": 3205, "regularMarketVolume": 3205, "averageVolume": 17561, "averageVolume10days": 13820, "averageDailyVolume10Day": 13820, "bid": 8.95, "ask": 8.97, "bidSize": 400, "askSize": 400, "marketCap": 229245296, "fiftyTwoWeekLow": 5.75, "fiftyTwoWeekHigh": 14.6, "priceToSalesTrailing12Months": 6.8712435, "fiftyDayAverage": 8.5136, "twoHundredDayAverage": 9.8809, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 251985984, "profitMargins": 0.34604, "floatShares": 14856612, "sharesOutstanding": 25614000, "sharesShort": 11427, "sharesShortPriorMonth": 48425, "sharesShortPreviousMonthDate": 1477872000, "dateShortInterest": 1480464000, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.41946, "heldPercentInstitutions": 0.01428, "shortRatio": 0.97, "impliedSharesOutstanding": 25627500, "bookValue": 3.998, "priceToBook": 2.2386193, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "earningsQuarterlyGrowth": -0.563, "netIncomeToCommon": 11545000, "trailingEps": 0.46, "forwardEps": 0.5, "enterpriseToRevenue": 7.553, "enterpriseToEbitda": 21.554, "52WeekChange": 0.43429482, "SandP52WeekChange": 0.07995045, "quoteType": "EQUITY", "currentPrice": 8.95, "recommendationKey": "none", "totalCash": 17837000, "totalCashPerShare": 0.696, "ebitda": 11691000, "totalDebt": 40578000, "quickRatio": 1.595, "currentRatio": 1.936, "totalRevenue": 33363000, "debtToEquity": 39.649, "revenuePerShare": 1.35, "returnOnAssets": 0.039470002, "returnOnEquity": 0.12627, "grossProfits": 24103000, "freeCashflow": -67755000, "operatingCashflow": 19546000, "earningsGrowth": -0.572, "revenueGrowth": 1.403, "grossMargins": 0.72245, "ebitdaMargins": 0.35042, "operatingMargins": 0.028250001, "financialCurrency": "USD", "symbol": "CPHRF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "shortName": "Cipher Pharmaceuticals, Inc.", "longName": "Cipher Pharmaceuticals Inc.", "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1138890600000, "regularMarketChange": 0.3000002, "regularMarketDayRange": "8.78 - 8.95", "fullExchangeName": "OTC Markets OTCQX", "averageDailyVolume3Month": 17561, "fiftyTwoWeekLowChange": 3.1999998, "fiftyTwoWeekLowChangePercent": 0.5565217, "fiftyTwoWeekRange": "5.75 - 14.6", "fiftyTwoWeekHighChange": -5.6500006, "fiftyTwoWeekHighChangePercent": -0.38698635, "fiftyTwoWeekChangePercent": 43.42948, "earningsTimestamp": 1742333393, "earningsTimestampStart": 1742333393, "earningsTimestampEnd": 1742333393, "earningsCallTimestampStart": 1742387400, "earningsCallTimestampEnd": 1742387400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.46, "epsForward": 0.5, "fiftyDayAverageChange": 0.43639946, "fiftyDayAverageChangePercent": 0.051259097, "twoHundredDayAverageChange": -0.9309006, "twoHundredDayAverageChangePercent": -0.09421212, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "corporateActions": [], "regularMarketTime": 1745609403, "exchange": "OQX", "messageBoardId": "finmb_8201659", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.4682105, "regularMarketPrice": 8.95, "marketState": "CLOSED", "displayName": "Cipher Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-04-26"}]